Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 as a molecular target in breast cancer: a therapeutic perspective of gynecological cancer

Arch Pharm Res. 2019 Feb;42(2):128-139. doi: 10.1007/s12272-019-01122-3. Epub 2019 Jan 25.

Abstract

Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (PIN1) induces conformational and functional changes to numerous key signaling molecules following proline-directed phosphorylation and its deregulation contributes to disease, particularly cancer. PIN1 is overexpressed in breast cancer, promoting cell proliferation and transformation in collaboration with several oncogenic signaling pathways, and is correlated with a poor clinical outcome. PIN1 level is also increased in certain gynecological cancers such as cervical, ovarian, and endometrial cancers. Although women with breast cancer are at risk of developing a second primary gynecological malignancy, particularly of the endometrium and ovary, the common oncogenic signaling pathway mediated by PIN1 has not been noted to date. This review discusses the roles of PIN1 in breast tumorigenesis and gynecological cancer progression, as well as the clinical effect of targeting this enzyme in breast and gynecological cancers.

Keywords: Breast cancer; Gynecological cancer; PIN1; Post-phosphorylation signaling.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / metabolism
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism*
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Female
  • Genital Neoplasms, Female / drug therapy
  • Genital Neoplasms, Female / metabolism*
  • Humans
  • NIMA-Interacting Peptidylprolyl Isomerase / antagonists & inhibitors
  • NIMA-Interacting Peptidylprolyl Isomerase / metabolism*
  • Protein Binding / physiology

Substances

  • Antineoplastic Agents
  • NIMA-Interacting Peptidylprolyl Isomerase
  • PIN1 protein, human